i tuoi badge Intervallo 52 sett. $12–$21 0% of range Rating Analisti SELL 7 analysts Prezzo Obiettivo $12 +1% upside P/E -176.4 ROE -6.0% Margine di Profitto Netto -14.6%

AMRN Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

03
Prezzo $12.35
Capitalizzazione di Mercato (MRQ) $5.19B
P/E (TTM) -176.4
EPS (TTM) $-0.07
Ricavi (TTM) $186M
ROE (TTM) -6.0%
Intervallo 52 sett. $12–$21

AMRN Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

04
intervallo
barre

La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.

Split azionari 3
Data ex-dividendo Split Tipo
11 Aprile 2025 1-for-20 Inverso
18 Gennaio 2008 1-for-10 Inverso
19 Ottobre 1998 1-for-10 Inverso

Informazioni su Amarin Corporation plc - American Depositary Shares Panoramica della società da Wikipedia

05 · wikidata

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.

History

Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.

In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.

Products and development

Vascepa (USA) / Vazkepa (EU)

Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.

Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.

HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.

On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.

Patent disputes

On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.

== Finance ==

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

settoreHealthcare industriaBiotechnology dipendenti80 paeseIE

Performance decennale Andamento di ricavi, utile netto, margini e EPS

06
Ricavi$214M
2016-12-31 → 2025-12-31
EPS$-0.09
2016-12-31 → 2025-12-31
Flusso di cassa libero·
2016-12-31 → 2020-12-31
Margine netto-14.6%
2016-12-31 → 2025-12-31
Valutazione e Rapporti 07–12

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica Tendenza 5 anni AMRN media 5 anni Mediana dei peer Verdetto
P/E (TTM) -176.4media 5 anni ≈591.4 ≈591.4 · ·
P/S (TTM) 27.9media 5 anni ≈22.7 ≈22.7 · ·
P/B (MRQ) 11.7media 5 anni ≈11.3 ≈11.3 · ·
Price / Cash Flow (Prezzo / Flusso di cassa) 764.0media 5 anni ≈589.2 ≈589.2 · ·
Prezzo / Valore contabile tangibile (MRQ) 12.0media 5 anni ≈18.7 ≈18.7 · ·

La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.

valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

14
Sorpresa media 49.9%
Prossimo report Ott 27, 2026
PeriodoRapportoEPS ActualEPS StimatoSorpresa
30 Giugno 2026 Lug 28, 2026 $-0.02 $-0.01 -96.1%
31 Marzo 2026 $-0.09 $0.09 -203.8%
31 Dicembre 2025 $0.01 $0.00 —
30 Settembre 2025 $0.08 $-0.58 113.8%
30 Giugno 2025 $0.66 $-0.18 466.3%
31 Marzo 2025 $-0.76 $-0.58 -30.7%

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

15
Conto Economico 18
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Cost of Revenue ····$121M$131M$96M$55M$45M$34M$28M$20M
Gross Profit $121M$81M$166M$242M$462M$483M$334M$175M$136M$96M$54M$34M
R&D Expense $20M$21M$22M$30M$29M$39M$34M$56M$47M$50M$51M$50M
SG&A Expense $115M$152M$200M$304M$408M$463M$324M$227M$135M$111M$101M$79M
Operating Expenses $171M$173M$233M$348M$451M$502M$358M$283M$182M$161M$152M$130M
Operating Income $-50M$-92M$-68M$-106M$11M$-20M$-24M$-108M$-46M$-66M$-98M$-96M
Interest Expense $7.0K$7.0K$8.0K$15.0K$129.0K$3M$7M$9M$10M$19M$20M$19M
Interest Income $11M$13M$12M$3M$1M$5M$8M$1M$429.0K$234.0K$132.0K$96.0K
Other Non-op $3M$1M$2M$-740.0K$-302.0K$104.0K$-75.0K$-326.0K$74.0K$-482.0K$-228.0K$4M
Pretax Income $-36M$-77M$-54M$-104M$11M$-17M$-22M$-116M$-55M$-76M$-118M$-59M
Income Tax $3M$5M$5M$2M$4M$745.0K$164.0K$96.0K$13M$10M$-3M$-3M
Net Income $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
EPS (Basic) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.32
EPS (Diluted) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Shares (Basic) 414,984,000410,937,000407,655,000401,155,000395,992,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,719,000
Shares (Diluted) 414,984,000410,937,000407,655,000401,155,000402,480,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,824,000
EBITDA $-50M$-92M$-68M··$-20M·$-108M$-46M$-66M$-98M$-96M
Stato Patrimoniale 27
Metrica Tendenza 202520242023202220212020201920182017201620152014
Cash & Equivalents $135M$121M$199M$218M$219M$187M$645M$249M$74M$98M$107M$120M
Short-term Investments $168M$173M$121M$92M$235M$314M······
Receivables $127M$122M$134M$131M$164M$155M$116M$67M$45M$20M$14M$8M
Inventory $196M$166M$259M$229M$235M$189M$77M$58M$30M$21M$19M$14M
Prepaid Expense $24M$13M$12M$19M$22M$31M$13M$3M$3M$7M$3M$3M
Other Current Assets ···········$3M
Current Assets $650M$595M$725M$689M$879M$879M$855M$378M$153M$146M$144M$145M
PP&E (Net) $12.0K$16.0K$114.0K$874.0K$1M$2M$2M$63.0K$28.0K$78.0K$243.0K$381.0K
PP&E (Gross) $1M$1M$1M$3M$3M$4M$3M$902.0K$844.0K$821.0K$997.0K$969.0K
Accum. Depreciation $1M$1M$1M$2M$2M$2M$1M$839.0K$816.0K$755.0K$754.0K$588.0K
Intangibles $13M$16M$19M$22M$24M$14M$15M$7M$8M$9M$9M$10M
Other Non-current Assets $1M$1M$1M$458.0K$456.0K$432.0K$1M$174.0K$174.0K$741.0K$174.0K$3M
Total Assets $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Accounts Payable $45M$40M$53M$65M$115M$106M$50M$38M$25M$6M$11M$9M
Current Liabilities $194M$180M$259M$259M$371M$307M$242M$157M$109M$76M$51M$40M
Capital Leases $6M$8M$9M$10M$9M$9M$9M·····
Other Non-current Liabilities $11M$12M$9M$8M$8M$6M$4M$11M$1M$710.0K$335.0K$386.0K
Total Liabilities $211M$199M$280M$291M$401M$339M$274M$233M$227M$176M$301M$260M
Long-term Debt ······$50M$80M$92M$94M$92M$105M
Total Debt ·····$0·$80M$93M$101M$106M$105M
Common Stock $310M$305M$303M$299M$294M$290M$269M$247M$209M$207M$150M$143M
Paid-in Capital $1.92B$1.91B$1.90B$1.89B$1.86B$1.82B$1.76B$1.28B$978M···
Retained Earnings $-1.71B$-1.67B$-1.59B$-1.53B$-1.42B$-1.43B$-1.41B$-1.39B$-1.27B$-1.20B$-1.12B$-970M
Treasury Stock $67M$65M$64M$62M$61M$51M$36M$10M$4M$1M$411.0K$217.0K
Stockholders' Equity $459M$486M$552M$595M$667M$628M$608M$152M$-65M$-9M$-129M$-88M
Liabilities + Equity $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Shares Outstanding 416,214,102411,584,851408,824,093408,824,093396,598,008392,538,081360,103,901325,850,013271,022,011269,363,696183,403,263174,590,372
Flusso di cassa 17
Metrica Tendenza 202520242023202220212020201920182017201620152014
D&A ·······$23.0K$62.0K$138.0K$166.0K$198.0K
Stock-based Comp $14M$18M$16M$26M$37M$46M$31M$19M$14M$14M$14M$9M
Deferred Tax ········$11M$9M$-4M$-4M
Amort. of Intangibles $3M$3M$3M$3M$2M$1M$679.0K$646.0K$646.0K$645.0K$646.0K$646.0K
Restructuring $36M$0$11M$14M$14M·······
Operating Cash Flow $7M$-31M$7M$-180M$-67M$-22M$-9M$-95M$-33M$-72M$-84M$-75M
CapEx ·····$252.0K$2M$58.0K$12.0K$21.0K$28.0K·
Investing Cash Flow $9M$-46M$-26M$175M$104M$-377M$-2M$-58.0K$-12.0K$-21.0K··
Net Debt Issued ·····$-50M·$-15M$-3M···
Stock Issued ······$440M$265M·$65M··
Stock Repurchased ··········$194.0K·
Net Stock Activity ·······$265M·$65M$-194.0K·
Financing Cash Flow $-2M$-1M$230.0K$-379.0K$-5M$-59M$410M$271M$8M$63M··
Net Change in Cash $14M$-78M$-18M$-5M$32M$-458M$398M$176M$-25M$-9M$-13M$-72M
Taxes Paid $1M$4M$2M$-2M$4M$-207.0K$-67.0K·····
Free Cash Flow ·····$-22M·$-95M$-33M$-72M$-85M·
Levered FCF ·····$-25M·$-104M$-45M$-93M$-104M·
Redditività 8
Metrica Tendenza 202520242023202220212020201920182017201620152014
Gross Margin 56.6%35.6%53.9%··78.6%·76.2%75.2%73.6%65.9%62.2%
Operating Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
Net Margin -18.2%-35.9%-19.3%··-2.9%·-50.8%-37.5%-66.4%-140.9%-104.0%
Pretax Margin -16.9%-33.8%-17.5%··-2.8%·-50.8%-30.3%-58.7%-144.7%-109.2%
EBITDA Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
ROA -5.7%-10.8%-6.9%··-1.9%·-42.5%-41.3%-50.8%-66.9%-26.6%
ROE -8.4%-16.2%-10.7%··-2.9%·-234.1%183.0%124.9%105.9%92.2%
ROIC -11.8%-20.1%-13.5%··-3.3%·-46.6%-200.8%-80.6%417.0%-551.6%
Liquidità e Solvibilità 5
Metrica Tendenza 202520242023202220212020201920182017201620152014
Current Ratio 3.33.32.8··2.9·2.41.41.92.83.6
Quick Ratio 2.22.31.8··2.1·2.01.11.62.43.2
Debt / Equity ·····0.0·0.5-1.4-11.2-0.8-1.2
LT Debt / Equity ·······0.3-1.1-9.4-0.7-1.0
Interest Coverage -7167.1-13113.9-8448.5··-7.5·-12.2-4.7-3.5-4.9-5.2
Efficienza 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Asset Turnover 0.30.30.4··0.7·0.81.10.80.50.3
Inventory Turnover ·····1.0·1.21.81.71.71.2
Receivables Turnover 1.71.82.3··4.5·4.15.57.77.59.4
Per Azione 5
Metrica Tendenza 202520242023202220212020201920182017201620152014
Book Value / Share $1.10$1.18$1.35··$1.60·$0.47$-0.24$-0.03$-0.70$-0.51
Revenue / Share $0.51$0.56$0.75··$1.61·$0.77$0.67$0.61$0.45$0.31
Cash Flow / Share $0.02$-0.08$0.02··$-0.06·$-0.32$-0.12$-0.34$-0.47$-0.42
Cash / Share $0.32$0.29$0.49··$0.48·$0.76$0.27$0.36$0.58$0.68
EPS (TTM) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Tassi di Crescita 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue YoY -6.6%-25.5%-16.9%-36.7%-5.0%·······
Revenue CAGR 3Y -16.7%-26.8%-20.6%·········
Revenue CAGR 5Y -19.0%···········
Valutazione (TTM) 14
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue TTM $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Net Income TTM $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
Market Cap $5.81B$4.03B$7.11B··$38.39B·$88.70B$21.74B$16.59B$6.93B$3.42B
Enterprise Value ·····$37.89B·$88.53B$21.76B$16.60B$6.93B$3.41B
P/E -155.1-49.0-116.0-93.13370.0-1956.0-6125.7-697.9-320.8-150.2-45.5-54.4
P/S 27.217.623.2··62.5·387.0120.0127.684.863.1
P/B 12.78.312.9··61.2·582.3-333.9-1831.8-53.7-38.7
P / Tangible Book 13.08.613.417.141.562.6······
P / Cash Flow 863.6-130.01033.9··-1765.4·-936.6-661.9-231.0-81.8-47.3
P / FCF ·····-1745.2·-936.0-661.7-231.0-81.8·
EV / EBITDA ·····-1927.7·-818.0-477.6-252.9-70.6-35.5
EV / FCF ·····-1722.4·-934.2-662.3-231.0-81.8·
EV / Revenue ·····61.7·386.2120.1127.684.862.9
Earnings Yield -0.64%-2.0%-0.86%-1.1%0.03%-0.05%-0.02%-0.14%-0.31%-0.67%-2.2%-1.8%

Periodo più recente a sinistra · valori nulli mostrati come ·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

16
Metrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ricavi $214M $229M $307M $369M $583M
Margine Lordo % 56.6% 35.6% 53.9% · ·
Margine Operativo % -23.5% -40.2% -22.0% · ·
Utile netto $-39M $-82M $-59M $-106M $8M
EPS Diluito $-0.09 $-0.20 $-0.15 $-0.26 $0.02

Proprietari istituzionali (13F) 88 filer · $64.3M totale · Aggiornato al 30 Giugno 2026

17

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Detentori 88
Valore detenuto $64.3M
Nuove posizioni 21
Posizioni chiuse 7
Attività istituzionale — Q2 2026 vs trimestre precedente
Nuove posizioni Posizioni chiuse Aumentato Diminuito Variazione netta delle azioni
21 (+13 vs trimestre precedente) 7 (-12 vs trimestre precedente) 16 (-3 vs trimestre precedente) 14 (-1 vs trimestre precedente) +79K

Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.

Istituzione Valore Azioni % di 13F tracciati Tipo
Sarissa Capital Management LP $26.673.916 1.673.395 41,49% Azioni
Kynam Capital Management, LP $8.495.733 532.982 13,22% Azioni
MORGAN STANLEY $3.564.456 223.617 5,54% Azioni
Waterfront Wealth Inc. $3.183.561 213.949 4,95% Azioni
Brooklands Fund Management Ltd $2.741.449 177.325 4,26% Azioni
Eversept Partners, LP $2.316.018 145.296 3,60% Azioni
MILLENNIUM MANAGEMENT LLC $1.845.980 115.808 2,87% Azioni
TWO SIGMA INVESTMENTS, LP $1.602.145 100.511 2,49% Azioni
CITADEL ADVISORS LLC $1.520.103 95.364 2,36% Azioni
BNP PARIBAS FINANCIAL MARKETS $1.144.699 71.813 1,78% Azioni
LCM Capital Management Inc $818.710 51.362 1,27% Azioni
RENAISSANCE TECHNOLOGIES LLC $771.002 48.369 1,20% Azioni
SUSQUEHANNA INTERNATIONAL GROUP, LLP $765.120 48.000 1,19% Opzione Call
JANE STREET GROUP, LLC $599.790 37.628 0,93% Azioni
George Kaiser Family Foundation $593.080 37.207 0,92% Azioni
TWO SIGMA ADVISERS, LP $516.265 36.995 0,80% Azioni
SEI INVESTMENTS CO $465.628 29.211 0,72% Azioni
SUSQUEHANNA INTERNATIONAL GROUP, LLP $462.276 29.001 0,72% Azioni
STATE STREET CORP $398.755 25.016 0,62% Azioni
SUSQUEHANNA INTERNATIONAL GROUP, LLP $385.748 24.200 0,60% Opzione Put
Bleakley Financial Group, LLC $374.670 23.505 0,58% Azioni
AMERIPRISE FINANCIAL INC $302.573 18.982 0,47% Azioni
State of New Jersey Common Pension Fund D $300.931 18.879 0,47% Azioni
CITADEL ADVISORS LLC $299.672 18.800 0,47% Opzione Put
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS $292.818 18.370 0,46% Azioni
RAYMOND JAMES FINANCIAL INC $289.550 18.165 0,45% Azioni
R Squared Ltd $269.992 16.938 0,42% Azioni
State of Tennessee, Department of Treasury $239.164 15.004 0,37% Azioni
Quadrature Capital Ltd $236.581 14.842 0,37% Azioni
Quinn Opportunity Partners LLC $228.022 14.305 0,35% Azioni
Cubist Systematic Strategies, LLC $224.390 13.699 0,35% Azioni
WELLS FARGO & COMPANY/MN $221.773 13.913 0,34% Azioni
EntryPoint Capital, LLC $194.882 12.226 0,30% Azioni
Jump Financial, LLC $191.407 12.008 0,30% Azioni
GEODE CAPITAL MANAGEMENT, LLC $187.629 11.771 0,29% Azioni
OSAIC HOLDINGS, INC. $184.333 11.565 0,29% Azioni
NJ State Employees Deferred Compensation Plan $178.542 10.900 0,28% Azioni
Verdad Advisers, LP $166.270 10.431 0,26% Azioni
CITADEL ADVISORS LLC $164.182 10.300 0,26% Opzione Call
UBS Group AG $160.404 10.063 0,25% Azioni
Steward Partners Investment Advisory, LLC $142.025 8.910 0,22% Azioni
NEW YORK STATE COMMON RETIREMENT FUND $121.224 7.605 0,19% Azioni
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO $92.038 5.774 0,14% Azioni
Federation des caisses Desjardins du Quebec $73.518 4.615 0,11% Azioni
RHUMBLINE ADVISERS $59.498 3.733 0,09% Azioni
NATIONAL BANK OF CANADA /FI/ $40.137 2.518 0,06% Azioni
ROYAL BANK OF CANADA $30.000 1.877 0,05% Azioni
GAMMA Investing LLC $25.121 1.576 0,04% Azioni
NewEdge Advisors, LLC $21.471 1.347 0,03% Azioni
Farther Finance Advisors, LLC $15.271 958 0,02% Azioni

Mostra tutti i 88 proprietari istituzionali →

Attivisti e proprietari del 5%+ 35 partecipazioni

18

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Depositante Depositato Partecipazione Stato Scopo Deposito
Alexander J Denner, Sarissa Capital Management LP 27 Agosto 2026 6,09% Modifica · SEC
Sarissa Capital Management LP, Alexander J Denner ×3 depositi 25 Marzo 2025 8,08% Modifica Campagna per il consiglio di amministrazione SEC
28 Febbraio 2023 · Deposito iniziale · SEC
27 Febbraio 2023 · Deposito iniziale · SEC
21 Febbraio 2023 · Deposito iniziale · SEC
OR ×6 depositi 15 Febbraio 2023 · Deposito iniziale · SEC
14 Febbraio 2023 · Deposito iniziale · SEC
10 Febbraio 2023 · Deposito iniziale · SEC
19 Gennaio 2023 · Deposito iniziale · SEC
16 Giugno 2022 · Deposito iniziale · SEC
Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 depositi 23 Agosto 2013 · Deposito iniziale Investimento passivo SEC
Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 depositi 22 Luglio 2013 · Deposito iniziale Campagna per il consiglio di amministrazione SEC
Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 depositi 24 Agosto 2011 · Deposito iniziale · SEC
OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 depositi 28 Aprile 2011 · Deposito iniziale · SEC
Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 depositi 10 Dicembre 2010 · Deposito iniziale · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insider aziendali 43 insider · 18 dirigenti · 27 direttori

19
Insider Ruolo Ultima attività Azioni possedute Acquisti 12m Vendite 12m Netto 12m
Aaron Berg President and CEO 26 Giugno 2026 M 85.648 0 0 $0
Patrick Holt President and CEO 22 Gennaio 2024 P 314.426 0 0 $0
Karim Mikhail President and CEO 21 Febbraio 2023 A 283.507 0 0 $0
John F Thero President and CEO 30 Luglio 2021 M 3.252.752 0 0 $0
Peter L. Fishman SVP, CFO 01 Agosto 2026 A 7.619 0 0 $0
Thomas Charles Reilly EVP and CFO 01 Luglio 2024 M 94.305 0 0 $0
Michael Wayne Kalb SVP and CFO 29 Luglio 2022 M 337.314 0 0 $0
David Paul Keenan EVP, Chief Operating Officer 01 Luglio 2026 A 13.470 0 0 $0
Jonathan Provoost EVP, Chief Legal Officer 01 Luglio 2026 A 4.624 0 0 $0
Steven B Ketchum EVP, Chief Scientific Officer 01 Luglio 2026 A 42.680 0 0 $0
Jason M. Marks EVP,Chief Global Legal Officer 19 Agosto 2022 M 21.917 0 0 $0
Joseph T Kennedy General Counsel 30 Luglio 2021 M 317.860 0 0 $0
Mark Salyer Chief Commercial Officer 01 Febbraio 2018 A · 0 0 $0
Michael James Farrell VP, Finance 01 Febbraio 2016 A 30.190 0 0 $0
Paul Huff Chief Commercial Officer 26 Luglio 2012 A 0 0 0 $0
Stuart D Sedlack Senior Vice President 26 Luglio 2012 A 0 0 0 $0
Paresh Soni SVP and Head of Development 01 Febbraio 2012 A 0 0 0 $0
Frederick W Ahlholm Vice President Finance 01 Febbraio 2012 A 0 0 0 $0
Oliver O'Connor Direttore 18 Aprile 2026 M 801 0 0 $0
Paul Cohen Direttore 18 Aprile 2026 M 836 0 0 $0
Diane E. Sullivan Direttore 18 Aprile 2026 M 836 0 0 $0
Louis Sterling III Direttore 18 Aprile 2026 M 4.049 0 0 $0
Patrice Eadon Bonfiglio Direttore 18 Aprile 2026 M 836 0 0 $0
Keith Horn Direttore 18 Aprile 2026 M 836 0 0 $0
Odysseas D Kostas Direttore 18 Aprile 2026 M 836 0 0 $0
Mark Dipaolo Direttore 18 Aprile 2025 M 401 0 0 $0
Olsen Per Wold Direttore 10 Gennaio 2023 M 171.027 0 0 $0
Murray Stewart Direttore 09 Gennaio 2023 A · 0 0 $0
Adam Mark Berger Direttore 20 Ottobre 2022 A · 0 0 $0
Geraldine Murphy Direttore 20 Ottobre 2022 A · 0 0 $0
Alfonso G Zulueta Direttore 27 Giugno 2022 A · 0 0 $0
Erin S. Enright Direttore 27 Giugno 2022 A · 0 0 $0
Kristine Peterson Direttore 27 Giugno 2022 A 0 0 0 $0
Patrick J O'Sullivan Direttore 27 Giugno 2022 A · 0 0 $0
Lars Ekman Direttore 27 Giugno 2022 A 0 0 0 $0
VAN HEEK G JAN Direttore 27 Giugno 2022 A 14.168 0 0 $0
Joseph S Zakrzewski Direttore 15 Dicembre 2021 P 196.547 0 0 $0
David M Stack Direttore 14 Giugno 2021 A 40.000 0 0 $0
Dr. James I. Healy Direttore 11 Luglio 2016 A 90.000 0 0 $0
GORDON CARL L Direttore 04 Settembre 2012 S 5.700 0 0 $0
Joseph Anderson Direttore 10 Luglio 2012 A 11.683 0 0 $0
David W Feigal Jr Direttore 12 Luglio 2011 A · 0 0 $0
Abingworth LLP Proprietario del 10% 19 Aprile 2012 S 1.599.168 0 0 $0

Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato

AMRN Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

21
rating · 7 analisti VENDI
Target mediano $12.50 +1,2%
0 0,0% Acquisto forte
0 0,0% Compra
2 28,6% Mantieni
3 42,9% Vendi
2 28,6% Vendita forte

Target Price a 12 Mesi

2 analisti · 2026-10-03

Target medio $12.50 +1,2%

Ora Prezzo attuale $12.35
Basso$12.00 Media$12.50 Alto$13.00

Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore

22

Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.

Ticker Capitalizzazione di Mercato P/E Rev YoY Margine Netto ROE Margine lordo
AMRN $5.81B -155.1 -6.6% -18.2% -8.4% 56.6%
ALKS $4.63B 19.6 -5.2% 16.4% 14.0% ·
PRTA $514M -2.1 -92.8% -2520.6% -63.6% ·

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

26

Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

Fonte: SEC 10-Q depositato Lug 29, 2026